Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Piperacillin→

Piperacillin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
61477-96-1
Molecular formula
C23H27N5O7S
Molecular weight
517.6 g/mol
Drug class
Extended-spectrum ureidopenicillinbeta-lactam antibacterial agent
Mechanism of action
Binds penicillin-binding proteins and inhibits bacterial septum formation and cell-wall synthesis, resulting in bactericidal activity against susceptible organisms. It is commonly administered with tazobactam to inhibit susceptible beta-lactamases.
Indications / reported uses
  • Treatment of susceptible serious bacterial infections, including intra-abdominal, respiratory, skin/soft-tissue and other systemic infections; product combinations and indications depend on the specific authorised formulation.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db6bd91-2106-4bfd-8cc8-38aaf1e18d17 · https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ab9d90d-2f7f-4599-a44f-3d0a8f8ab623

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Piperacillin Environmental Risk Assessment (ERA) (the Piperacillin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.